Table S3.
Correlation between the expression of the enzymes generating OCDO and the histological grade and subtypes of patient tumors
| Enzyme | Histological grade | HER2 and hormone receptor status | ||||||||||||
| I | II | III | P | HER2− | HER2+ | P | ER−/PR− | ER+/PR− | ER+/PR+ | P | TN | P | ||
| No | Yes | |||||||||||||
| 11HSD2 | n = 7 | n = 17 | n = 21 | n = 36 | n = 9 | n = 11 | n = 7 | n = 27 | n = 40 | n = 5 | ||||
| Low IRS (0–6) | 4/34 | 16/34 | 14/34 | 0.0417 | 30/34 | 4/34 | 0.0275 | 8/34 | 4/34 | 22/34 | ns | 30/34 | 4/34 | ns |
| n = 34, % | (11.8) | (47.1) | (41.2) | (88.2) | (11.8) | (23.5) | (11.8) | (64.7) | (88.2) | (11.8) | ||||
| High IRS (7–12) | 3/11 | 1/11 | 7/11 | 6/11 | 5/11 | 3/11 | 3/11 | 5/11 | 10/11 | 1/11 | ||||
| n = 11, % | (27.3) | (9.1) | (63.6) | (54.5) | (45.5) | (27.3) | (27.3) | (45.5) | (90.9) | (9.1) | ||||
| DHCR7 | n = 7 | n = 18 | n = 20 | n = 36 | n = 9 | n = 12 | n = 7 | n = 26 | n = 39 | n = 6 | ||||
| Low IRS (0–6) | 7/37 | 18/37 | 12/37 | 0.0021 | 35/37 | 2/37 | <0.0001 | 7/37 | 5/37 | 25/37 | 0.0064 | 32/37 | 5/37 | ns |
| n = 37, % | (18.9) | (48.6) | (32.4) | (94.6) | (5.4) | (18.9) | (13.5) | (67.6) | (86.5) | (13.5) | ||||
| High IRS (7–12) | 0/8 | 0/8 | 8/8 | 1/8 | 7/8 | 5/8 | 2/8 | 1/8 | 7/8 | 1/8 | ||||
| n = 8, % | (0) | (0) | (100) | (12.5) | (87.5) | (62.5) | (25) | (12.5) | (87.5) | (12.5) | ||||
| D8D7I | n = 7 | n = 19 | n = 20 | n = 36 | n = 10 | n = 12 | n = 7 | n = 27 | n = 41 | n = 5 | ||||
| Low IRS (0–6) | 7/38 | 17/38 | 14/38 | ns | 31 | 7 | ns | 6 | 7 | 25 | 0.0038 | 36 | 2 | 0.0307 |
| n = 38, % | (18.4) | (44.7) | (36.8) | (81.6) | (18.4) | (15.8) | (18.4) | (65.8) | (94.7) | (5.3) | ||||
| High IRS([7–12) | 0/8 | 2/8 | 6/8 | 5/8 | 3/8 | 6/8 | 0/8 | 2/8 | 5/8 | 3/8 | ||||
| n = 8, % | (0) | (25) | (75) | (62.5) | (37.5) | (75) | (0) | (25) | (62.5) | (37.5) | ||||
IHC analyses were scored as described in SI Experimental Procedures and Table S4. ER+ and PR+ tumors were defined by at least 10% of tumor cells being positive for these receptors by IHC analysis. HER2+ tumors were defined by at least 10% of tumor cells being positive for HER2 expression by IHC or a positive in situ hybridation assay. ns, not significant; TN, triple negative (ER−, PR−, and HER2−). Correlations between tumor sample immunoreactive score (IRS) and pathological characteristics were analyzed using χ2 test or Fisher’s exact test.